Goldilocks Dilemma of Dose Titration in Heart Failure With Reduced Ejection Fraction
Key result
Targeting high-dose versus low-dose ACEi/ARB in HFrEF led to a modest reduction in all-cause mortality (RR 0.94; 95% CI 0.89-1.00) without a significant difference in hospitalizations.
Why the study?
Does targeting high doses of ACEi/ARB reduce mortality and hospitalizations compared to low doses in patients with HFrEF?
Population
9,171 patients with heart failure with reduced ejection fraction (HFrEF) pooled from 6 randomized trials
Comparison
High target doses of angiotensin-converting… vs Low target doses of ACEi or ARB
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Targeting high doses of ACEi/ARB in HFrEF provides a modest mortality benefit over low doses without significantly increasing adverse events, supporting guideline recommendations for dose titration.
Structured PICO
Does targeting high doses of ACEi/ARB reduce mortality and hospitalizations compared to low doses in patients with HFrEF?
P
Population
9,171 patients with heart failure with reduced ejection fraction included in a meta-analysis of 6 randomized trials comparing high versus low target doses of ACEi/ARB.
I
Intervention
High target doses of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)
C
Comparator
Low target doses of ACEi or ARB
O
Outcome
All-cause mortalityhard clinical
Main Result
Relative Risk: 0.94 (95% CI 0.89–1)
Targeting high doses of ACEi/ARB in HFrEF provides a modest mortality benefit over low doses without significantly increasing adverse events, supporting guideline recommendations for dose titration.
Limitations
- Lack of uniform background beta-blocker use
- Significant heterogeneity in the heart failure hospitalization analysis
- Inability to address specific patient subgroups such as those with ischemic heart disease, hypertension, and diabetes mellitus
- Significant heterogeneity in the heart failure hospitalization analysis (I2=52.8%)
- Inability to address specific patient subgroups, such as patients with ischemic heart disease, hypertension, and diabetes mellitus
Cite This Study
Allen et al. (2017) conducted an editorial in Heart failure with reduced ejection fraction (HFrEF) (n=9,171). High-dose ACEi/ARB vs. Low target dose ACEi/ARB was evaluated on All-cause mortality (RR 0.94, 95% CI 0.89-1.00). Targeting high-dose versus low-dose ACEi/ARB in HFrEF led to a modest reduction in all-cause mortality (RR 0.94; 95% CI 0.89-1.00) without a significant difference in hospitalizations.